Page Title
Drug Development Pipeline
ARCT-032 (LUNAR®-CF)
Status
Phase TwoTherapeutic Approach
Genetic Therapy
ARCT-032 is an inhaled messenger RNA (mRNA) therapy. It aims to deliver a full-length copy of CFTR mRNA to lung cells using a lipid-mediated delivery system called LUNAR®. Lung cells would then use the instructions in the mRNA to create functional CFTR protein. This type of therapy could work for any person with CF, including those with nonsense (also known as “x” or “stop”) and other rare mutations that do not respond to CFTR modulators.
Status
A Phase 2 study to test the safety, tolerability, and effectiveness of ARCT-032 in adults with CF is currently underway.
Sponsor
This program is sponsored by Arcturus Therapeutics and is partially funded by the Cystic Fibrosis Foundation. The study is being conducted within the Therapeutics Development Network.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More